Auto-SCT (ASCT) is widely used in first-line treatment of multiple myeloma (MM). However, most patients eventually relapse or have progression of disease (R/POD). Although precise knowledge of R/POD patterns would be important to generate evidence-based surveillance recommendations after ASCT, such data is limited in the literature, especially after introduction of the free light chain assay (FLCA). This retrospective study examined the patterns of R/POD after first-line ASCT in 273 patients, using established criteria. At the time of R/POD, only 2% of patients had no associated serological evidence of R/POD. A total of 85% had asymptomatic R/ POD, first detected by serological testing, whereas 15% had symptomatic R/POD with aggressive disease, early R/POD and short survival, with poor cytogenetics and younger age identified as risk factors. Although occult skeletal lesions were found in 40% of asymptomatic patients tested following serological R/POD, yearly skeletal surveys and urine testing were poor at heralding R/POD. We found a consistent association between paraprotein types at diagnosis and R/POD, allowing informed recommendations for appropriate serological monitoring and propose a new needed criterion using FLCA for patients relapsing by FLC only. Our findings provide important evidence-based recommendations that strengthen current monitoring guidelines after first-line ASCT in MM.
INTRODUCTION

Treatment guidelines endorsed by the International Myeloma
Working Group (IMWG) and the National Comprehensive Cancer Network for patients with multiple myeloma (MM) under the age of 65 include an induction treatment followed by auto-SCT (ASCT). [1] [2] [3] [4] Over the past decade, the incorporation of novel therapeutic agents, such as bortezomib, thalidomide and lenalidomide, in this treatment schema has significantly improved response rate and PFS. 5, 6 However, despite these encouraging achievements, most, if not all, patients eventually develop relapse or progression of disease (R/POD). 4, 7 Although precise knowledge of R/POD patterns would be important to generate evidence-based surveillance recommendations after ASCT, such data is limited in the literature, especially in the era of novel therapies and following the introduction of the free light chain assay (FLCA). [8] [9] [10] In a retrospective analysis of 280 patients, Alegre et al. 11 recognized four distinct R/POD patterns after ASCT: extramedullary disease (14%), plasma cell leukemia (2%), clinically symptomatic disease (66%) and asymptomatic disease with insidious increase in serum monoclonal protein (18%). Another study by Lenhoff et al. 12 prospectively followed 313 patients who underwent ASCT for MM between 1994 and 1997. The authors identified four similar patterns of relapse: insidious or asymptomatic disease (31%), classical or symptomatic disease along with increase in serum and/or urine monoclonal component (51%), extramedullary disease (14%) and transformed disease (4%), such as plasmacytic leukemia and immunoblastic lymphoma. 11, 12 Both studies present drawbacks that may limit their relevance to currently treated patients with MM. Although both studies identified distinct patterns of relapse, neither study provided a clear definition of R/POD, the modality of identification and frequency of patients' monitoring. Furthermore, the development of novel treatment regimens and the introduction of the serum FLCA may limit the applicability of these studies to MM patients treated in the current era.
This retrospective study examines the patterns of R/POD after first-line ASCT in the current era, incorporating novel treatment regimens, current consensus R/POD definitions and the availability of FLC monitoring. We evaluate the utility of different diagnostic monitoring modalities with the ultimate goal of deriving evidencebased recommendations for optimal surveillance of patients post ASCT.
METHODS
Patient population
2009, as part of first-line therapy. We excluded from the analysis: patients transplanted 41 year after initiation of induction treatment, which we considered inconsistent with the current standard of care; patients whose response to transplant could not be assessed at 2-3 months post transplantation due to transfer of care to other institutions, lack of a baseline evaluation or death during the first 3 months post transplantation; patients with associated malignancies; and patients who received tandem autologous allogeneic transplantation. Patients who transferred care after a limited length of follow-up at the Memorial Sloan Kettering Cancer Center were retained for analysis, but their follow-up was limited to the period of monitoring at the Memorial Sloan Kettering Cancer Center.
Retrospective data collection
This study was approved by the Institutional Review Board. Data on baseline and treatment characteristics, response status and monitoring data prior to R/POD were collected from a database of all MM patients who underwent ASCT. Baseline and treatment characteristics analyzed are detailed in Table 1 . Risk assessment by cytogenetics used karyotyping and FISH analyses. High-risk patients included those with deletion 13, deletion p53, translocations t(4 : 14) and t(14 : 16), amplification 1q23 and complex cytogenetics. 13 The patients received various induction regimen and some received maintenance therapy post ASCT. Best response to ASCT was assessed 2-3 months after ASCT. The time of R/POD was the time of serological or clinical R/POD.
Criteria used for the determination of R/POD
The standard IMWG criteria for disease response, relapse and progression were used for determination of serological, urinary and clinical R/POD. 9, [14] [15] [16] Because immunohistochemical or flow-cytometric analyses were not available on all patients who achieved a CR, patients with confirmed stringent CR and CR were grouped together into the CR group. Furthermore, flow cytometry and molecular studies were not used for detection of minimal residual disease or R/POD. Because the IMWG criteria do not have provisions pertaining to patients relapsing from CR, whose relapse is detected solely by the FLCA, we adopted a new relapse criterion found to be common to all such patients: to be considered relapsing from CR, a patient had to have an abnormal FLC ratio and an elevated level of involved FLC preceded by a normal FLC ratio on at least two prior measurements. The abnormal findings had to be confirmed on a subsequent measurement that additionally showed a rise in the abnormal involved FLC level by at least 50%.
Strategy used for determination of R/POD
The strategy adopted in this study consisted of several steps (Figure 1 ). First, we reviewed electronic medical records to identify patients who had serological R/POD and determined the date of serological R/POD. Second, all patients, those with and without serological R/POD, were examined to determine whether clinical R/POD (anemia, renal failure, hypercalcemia, soft tissue or symptomatic bone lesions) had coincided with or anteceded serological R/POD, in which case the patients were labeled symptomatic R/ POD. All other patients with serological R/POD only were labeled asymptomatic R/POD. Further analysis was done on these subgroups of patients.
Statistical analysis
Among patients with R/POD, the univariate association between the type of R/POD and key patient and clinical characteristics was assessed using t-tests or Fisher's exact tests as appropriate. Kaplan-Meier survival curves and the logrank test were used to compare the time from R/POD to death for the asymptomatic and symptomatic groups. Cox proportional hazards regression was implemented to compare the risk of death adjusted for the potential difference in lag time between ASCT and R/POD in these two groups. Significance was defined as Po0.05 based on two-sided tests. Statistical analyses were conducted using R statistical software. 17 Table 1 . Cytogenetic studies for del17p and t(4;14) were only available after 2005. Therefore, complete cytogenetic testing was only available in 185 patients. The majority of patients received induction treatments based on thalidomide, lenalidomide, bortezomib or combination of these drugs (Table 1) . 
RESULTS
Patient
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The majority of R/POD is associated with serological evidence of R/POD Among 273 eligible patients, 173 had serological R/POD post transplant. Analysis of 100 remaining patients revealed 6 additional patients who met the IMWG clinical criteria for R/POD without evidence of serological R/POD, though 2 among them had no serological data available on the date of R/POD and therefore had inadequate serological follow-up. In addition, one patient relapsed with leptomeningeal disease, one with plasma cell leukemia and two had oligo-secretory disease. Interestingly, one of the latter two patients had IgA gammopathy and exhibited rising IgA levels steadily, preceding symptomatic relapse without meeting the IMWG serological criteria for R/POD. Excluding patients with no serological follow-up, only four patients (2%) had symptomatic R/POD without evidence of serological R/POD.
The majority of patients with R/POD have asymptomatic R/POD In addition to the 6 patients who had symptomatic R/POD in the absence of serological findings, 20 patients with serological R/POD had concurrent evidence of clinical/radiological R/POD (symptomatic group). These 26 patients exhibited often coinciding clinical findings consistent with aggressive disease, including acute severe anemia (n ¼ 5), leptomeningeal relapse (n ¼ 2), soft tissue involvement (n ¼ 14), plasma cell leukemia (n ¼ 1), symptomatic skeletal lesions (n ¼ 21), renal failure (n ¼ 1) and hypercalcemia (n ¼ 1). In this group, four out of five patients with IgA gammopathy had steady rise in their IgA level from baseline without meeting the IMWG criteria for serological R/POD prior to symptomatic R/POD. Although this study is not designed to determine the optimal serological follow-up interval post transplantation, 5 of the 26 symptomatic patients had intervals ranging from 143 to 469 days, probably contributing to their symptomatic presentation. The remaining 153 out of 179 patients with R/POD (85%) had isolated serological R/POD without conspicuous evidence of concomitant clinical R/POD (asymptomatic group). There was evidence by univariate association that symptomatic patients tend to have younger age, high-risk cytogenetics and shorter time from ASCT to R/POD (Table 2) . Further, attesting to the aggressive nature of the disease in symptomatic patients, the survival curves in Figure 2 show considerable separation in the time from relapse to death. Adjusting for the lag time between ASCT and relapse, the risk of death was significantly higher for the symptomatic group (hazard ratio: 3.43 (2.09, 5.63), Po0.001).
Role of imaging at the time of serological R/POD in patients with asymptomatic R/POD To determine whether patients in the asymptomatic group exhibited occult radiographic R/POD, despite lack of suspicion of clinical R/POD, we examined all patients who had radiological imaging within 4 weeks following the date of serological R/POD. A total of 64 out of 153 asymptomatic patients had routine imaging available. Twenty-five (40%) among them had new bone lesions by skeletal survey (SS) (n ¼ 12), PET/CT (n ¼ 11) or magnetic resonance imaging (MRI) (n ¼ 2), despite absence of any prior suspicion.
Role of yearly routine SS in the monitoring of patient with MM after ASCT To determine whether yearly routine SS is useful to monitor patients after ASCT, we reviewed SS within 1 year prior to the date of serological R/POD, available in 95 out of the 179 patients with R/POD. Only three patients (3%) had evidence of radiological R/ POD anteceding serological R/POD. All the three patients were in the symptomatic group with no serological follow-up on the day of radiological R/POD and had poor prior serological follow-up, ranging from 208 to 252 days.
Association between paraprotein types at times of diagnosis and R/POD To determine whether one could predict the pattern of serological R/POD in individual patients, and thereby identify the most appropriate serological testing for monitoring, we examined the association between the types of paraprotein at times of R/POD and diagnosis in patients who had complete serological data available. Determine the presence and date of serologic R/POD
Step 2 Determine the presence of other clinical R/POD in patients without serologic R/POD. Symptomatic R/POD n = 6
Step 3
Determine, as of the date of serologic R/POD, the presence of other clinical R/POD
Step 4 Univariate analyses of baseline and treatment characteristics Figure 1 . Overall study scheme. Overall, only 1 out of the 95 patients had symptomatic relapse, raising uncertainty regarding the clinical relevance of urine testing. Interestingly, this patient also had an IgA gammopathy.
DISCUSSION
In this retrospective study, we examined the patterns of R/POD in patients treated with induction therapy followed by ASCT. We have made several observations that could be relevant to the current monitoring guidelines of patients after ASCT. Based on this analysis, the overwhelming majority of R/POD is associated with concurrent serological R/POD, with only a small percentage of patients (2%) presenting with symptomatic clinical disease in the absence of serological R/POD. Furthermore, we find that the vast majority of patients with R/POD present with serological abnormalities as the initial manifestation of R/POD. Only 15% present with symptomatic overt clinical disease. Although the small number of patients in the latter group precludes a multivariate analysis, the univariate analysis indicates that poor cytogenetics, aggressive disease with early R/POD and younger age are associated with symptomatic R/POD. Further examination of this group also shows leukemic transformation, soft tissue involvement and leptomeningeal disease prominently featured at the time of R/POD. An important corollary of these observations would be that monitoring patients after ASCT with serological testing appears to be adequate in heralding the occurrence of R/POD, except for a minority of patients who have biologically aggressive disease, predicted by poor cytogenetics Denominator includes only those with an observed value. Figure 2 . Kaplan-Meier estimates of OS from the time of R/POD for the symptomatic and asymptomatic groups. The survival distributions for the two groups were compared using the logrank test.
Multiple myeloma relapse patterns after transplant D Zamarin et al and manifested by aggressive patterns of transformed R/POD, early R/POD and poor survival as similarly described by others. 18 Interestingly, we observed retrospectively that patients with IgA gammopathy often tend to have progressive elevation in IgA levels, without meeting the IMWG criteria for R/POD by serum PEP prior to symptomatic R/POD. 15 We therefore caution that serological monitoring of these patients using the IMWG criteria alone may not be sufficient. The IgA-level measurements in these patients may be more revealing. The development and incorporation of the new Hevylite assay may well remedy this inadequacy of the currently available tests, as suggested by others. 19, 20 Although it appears that serological testing alone may well be adequate for monitoring patients after ASCT, it is also interesting to highlight that our observations may not fully support the IMWG recommendations regarding the specific type of laboratory testing needed during monitoring. Indeed, the IMWG consensus recommends the use of serum FLCA for serial monitoring and assessment of response in patients with oligo-secretory disease only and does not advocate its use for serial follow-up or relapse assessment in patients with measurable M spike 'due to lack of sufficient data to suggest that addition of FLCA to serum immunofixation electrophoresis (IFE) and serum PEP may improve patient outcomes'. 9 Furthermore, the IMWG consensus also states that 'it is important for a particular patient to use the same method for follow-up of disease'.
14 In contrast, our observations indicate that all patients should be followed using all the available serological testing, including serum PEP, immunofixation and FLCA, except for patients with FLC-only disease who always have serological R/POD detected by FLCA only. Indeed, among patients who had Ig-only or Ig/FLC disease at diagnosis, a substantial percentage present with abnormal FLC as first serological indicator of R/POD, which we show to be clinically relevant. This testing would particularly be useful for patients who lose expression of Ig heavy chain, a phenomenon coined by others as 'FLC-escape'. 21, 22 In this study, we further propose a new FLC criterion for patients who relapse from CR because the IMWG criteria have no provision pertaining to such patients. 9, 14 It consists of an abnormal FLC ratio and involved FLC level after at least two prior normal measurements, with subsequent confirmation of the abnormal measurements and demonstration of X50% further increase in the involved FLC. Supporting the clinical relevance of such a criterion, we find that at least 23% of the patients meeting this criterion have concurrent evidence of radiographic R/POD.
In this study, yearly imaging with SS was not useful for earlier detection of R/POD in any patients who had a SS within a year prior to serological R/POD. Thus, yearly SS cannot be recommended for routine follow-up in the absence of other evidence for Figure 3 . Association between the types of monoclonal protein present at diagnosis and R/POD. Only the patients who had complete set of serological testing available at diagnosis and R/POD were included for the analysis. Patients were analyzed on the basis of the best response achieved after ASCT (CR or oCR) and the type of paraprotein present at diagnosis and R/POD: FLC-only, intact Ig-only (Ig) and FLC with intact Ig (FLC þ Ig). Multiple myeloma relapse patterns after transplant D Zamarin et al R/POD. This observation supports the IMWG recommendation that was not previously clearly substantiated. 14 This statement, however, may not apply to MRI, which was found useful by investigators who showed a poor correlation between clinical CR and MRI CR in patients with more than seven focal lesions and superior survival with resolution of MRI focal lesions. 23 Based on these findings, the authors recommended routine use of MRI every 6 months until resolution of focal lesions and annually, thereafter, a recommendation awaiting validation. 23 On the other hand, among patients with asymptomatic R/POD, a significant percentage had evidence of occult new skeletal findings by MRI, PET or SS obtained within 4 weeks after serological R/POD, despite the complete lack of suspicion of progressive clinical disease. These findings suggest that imaging should be recommended in patients with serological R/POD to uncover potential occult lesions. This recommendation is in contrast with that of the IMWG consensus stating that in patients with relapsed disease, 'a SS may be indicated to detect possible lesions at risk for fracture. Other imaging studies (CT, MRI and PET-CT) may be indicated according to clinical circumstances'.
14 Uncovering these occult lesions is important because it would signify clinical relapse/ progression and would compel physicians, in agreement with the IMWG consensus, to initiate salvage therapy. 15 The role of urine testing has been controversial in the literature, with some arguing that it may be obsolete in the era of FLCA. [24] [25] [26] [27] In this study, urine testing was far less sensitive to detect R/POD because only a small percentage of patients with serological R/ POD had evidence of concomitant UIF/urine PEP abnormalities. However, UIF did herald serological R/POD in a small percentage of patients with CR, an observation of uncertain clinical relevance. We would therefore conclude that UIF/urine PEP could be helpful in the subset of patients achieving CR post ASCT, although clinical relevance needs to be further examined.
In summary, we have described the patterns of R/POD in patients with MM after ASCT and proposed evidence-based recommendations for monitoring and management (Table 3) . Our findings differ from previous reports in the literature. This discrepancy may reflect the use of the FLCA and better-defined criteria for R/POD established by the IMWG. Although we acknowledge the limitations of the study because of the retrospective nature of the analysis and the heterogeneity of the patient population, we believe that our findings may strengthen the current guidelines for monitoring patients with MM after ASCT and provide a blueprint for further validation studies, addressing our findings in large prospective populations.
